BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 21640482)

  • 1. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
    Rink M; Chun FK; Dahlem R; Soave A; Minner S; Hansen J; Stoupiec M; Coith C; Kluth LA; Ahyai SA; Friedrich MG; Shariat SF; Fisch M; Pantel K; Riethdorf S
    Eur Urol; 2012 Apr; 61(4):810-7. PubMed ID: 22277196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC; Yu HJ; Chang YH; Pan CC
    J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
    König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
    Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study.
    Dorin RP; Daneshmand S; Eisenberg MS; Chandrasoma S; Cai J; Miranda G; Nichols PW; Skinner DG; Skinner EC
    Eur Urol; 2011 Nov; 60(5):946-52. PubMed ID: 21802833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy.
    May M; Herrmann E; Bolenz C; Tiemann A; Brookman-May S; Fritsche HM; Burger M; Buchner A; Gratzke C; Wülfing C; Trojan L; Ellinger J; Tilki D; Gilfrich C; Höfner T; Roigas J; Zacharias M; Gunia S; Wieland WF; Hohenfellner M; Michel MS; Haferkamp A; Müller SC; Stief CG; Bastian PJ
    Eur Urol; 2011 May; 59(5):712-8. PubMed ID: 21296488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.
    Liang PI; Wu LC; Sheu JJ; Wu TF; Shen KH; Wang YH; Wu WR; Shiue YL; Huang HY; Hsu HP; Chen YH; Chen LT; Li CF; Liao AC
    J Clin Pathol; 2012 Sep; 65(9):802-7. PubMed ID: 22685262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response.
    Seiler R; Thalmann GN; Rotzer D; Perren A; Fleischmann A
    Mod Pathol; 2014 Jan; 27(1):87-95. PubMed ID: 23887292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.
    Mills RD; Turner WH; Fleischmann A; Markwalder R; Thalmann GN; Studer UE
    J Urol; 2001 Jul; 166(1):19-23. PubMed ID: 11435814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy.
    Denzinger S; Stoehr R; Schwarz S; Eichenseher N; Brockhoff G; Obermann EC; Knuechel R; Blaszyk H; Hartmann A; Wild PJ
    Int J Oncol; 2007 Oct; 31(4):793-802. PubMed ID: 17786310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
    Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
    Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
    Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
    Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
    Steven K; Poulsen AL
    J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.
    Wright JL; Lin DW; Porter MP
    Cancer; 2008 Jun; 112(11):2401-8. PubMed ID: 18383515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracapsular extension but not the tumour burden of lymph node metastases is an independent adverse risk factor in lymph node-positive bladder cancer.
    Seiler R; von Gunten M; Thalmann GN; Fleischmann A
    Histopathology; 2011 Mar; 58(4):571-8. PubMed ID: 21401697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
    Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
    Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High CD10 expression predicts favorable outcome in surgically treated lymph node-positive bladder cancer patients.
    Seiler R; von Gunten M; Thalmann GN; Fleischmann A
    Hum Pathol; 2012 Feb; 43(2):269-75. PubMed ID: 21835428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.